초록 ▼

The present invention relates to the use of hydroxymethyl-group-containing glycosaminoglycans, such as in particular hydroxymethyl-hyaluronic acid, for the treatment and prevention of infectious diseases or malignant or premalignant diseases, in particular of the skin or mucosa. The invention additi

The present invention relates to the use of hydroxymethyl-group-containing glycosaminoglycans, such as in particular hydroxymethyl-hyaluronic acid, for the treatment and prevention of infectious diseases or malignant or premalignant diseases, in particular of the skin or mucosa. The invention additionally provides a preparation method for glycosaminoglycans modified with hydroxymethyl groups.

대표청구항 ▼

1. A method for treating or preventing an infectious disease of the skin or mucosa caused by a viral infection, wherein the viral infection is caused by a papilloma virus or a herpes virus, comprising administering to a subject in need thereof an effective amount of a preparation consisting essentia

1. A method for treating or preventing an infectious disease of the skin or mucosa caused by a viral infection, wherein the viral infection is caused by a papilloma virus or a herpes virus, comprising administering to a subject in need thereof an effective amount of a preparation consisting essentially of hydroxymethyl-group-hyaluronic acid as the active agent, wherein one or more amino groups are substituted with hydroxymethyl, wherein the degree of hydroxymethylation is in the range from 200:1 (0.5%) to 1:1 (100%), formulated for use in the treatment or prevention of infectious diseases, wherein the hydroxymethyl-group-containing glycosaminoglycan is prepared by a method comprising: (i) providing hyaluronic acid,(ii) substituting one or more amino groups of the hyaluronic acid with hydroxymethyl groups, and(iii) purifying the hydroxymethyl-group-containing hyaluronic acid and removing any formaldehyde or residues of formaldehyde-releasing reagents; and one or more pharmaceutical excipients selected from the group consisting of an agent for adjusting the pH value, a stabilizing agent, a solubiliser, an agent which promotes penetration, a preservative and a gel forming agent, wherein the composition does not comprise taurolidine. 2. The method of claim 1, wherein the infectious disease is a disease of the skin or mucosa selected from a disease of body surfaces, of the gastrointestinal tract, of the urogenital tract or of the lungs. 3. The method of claim 1, wherein the degree of hydroxymethylation is in the range from 100:1 (1%) to 10:1 (10%). 4. The method of claim 1, wherein the hyaluronic acid in step (i) is obtained by biotechnological means. 5. The method of claim 4, wherein the hyaluronic acid in step (i) is isolated from transgenic bacteria. 6. The method of claim 5, wherein the hyaluronic acid in step (i) is isolated from B. subtilis or streptococcal cultures. 7. The method of claim 1, wherein the hydroxymethyl group-containing hyaluronic acid has —N(R)—CH2OH residues, wherein R═H or acetyl. 8. The method of claim 1, wherein the viral infection is caused by a papilloma virus. 9. The method of claim 1, wherein the hydroxymethyl-group-containing hyaluronic acid is formulated for local administration. 10. The method of claim 1, wherein the hydroxymethyl-group-containing hyaluronic acid is formulated for intradermal administration, for administration at the boundary of the dermo-epithelial junction or for topical administration. 11. The method of claim 1, wherein the hydroxymethyl-group-containing hyaluronic acid is present in uncrosslinked form. 12. The method of claim 1, wherein the hydroxymethyl-group-containing hyaluronic acid is selected from the group consisting of (i) long-chain hyaluronic acids having an average molecular weight (weight average) of at least 200 kD and(ii) short-chain hyaluronic acids having an average molecular weight (weight average) of up to 50 kD, or mixtures thereof. 13. The method of claim 1, wherein the hydroxymethyl-group-containing hyaluronic acid is present in crosslinked form. 14. The method of claim 13, wherein the degree of crosslinking is in the range from 0.1% to 10%. 15. The method of claim 1, wherein the hydroxymethyl-group-containing hyaluronic acid is present in the form of a mixture of uncrosslinked and crosslinked hyaluronic acids. 16. The method of claim 1, wherein the hydroxymethyl-group-containing hyaluronic acid is formulated as an injectable preparation, ointment, cream, lotion, gel, spray, tincture, flushing or infusion solution, drip solution, shampoo, occlusive film, powder or inhalable preparation. 17. A method for treating or preventing an infectious disease of the skin or mucosa caused by a viral infection, wherein the viral infection is caused by a papilloma virus or a herpes virus, comprising administering to a subject in need thereof an effective amount of a preparation consisting essentially of a hydroxymethyl-group-containing hyaluronic acid as the active agent, wherein one or more amino groups are substituted with hydroxymethyl, wherein the degree of hydroxymethylation is in the range from 200:1 (0.5%) to 1:1 (100%), wherein the hydroxymethyl-group-containing hyaluronic acid is prepared by a method comprising: (i) providing hyaluronic acid,(ii) substituting one or more amino groups of the hyaluronic acid with hydroxymethyl groups, and(iii) purifying the hydroxymethyl-group-containing hyaluronic acid and removing any formaldehyde or residues of formaldehyde-releasing reagents, in combination with at least one inhibitor of hyaluronic acid degradation; and one or more pharmaceutical excipients selected from the group consisting of an agent for adjusting the pH value, a stabilizing agent, a solubiliser, an agent which promotes penetration, a preservative and a gel forming agent, formulated for use in the treatment or prevention of a viral infection of the skin or mucosa, wherein the composition does not comprise taurolidine. 18. The method of claim 16, wherein the inhalable preparation is an aerosol.